Abstract
Remimazolam is a novel intravenous ultrashort acting benzodiazepine that has a potential for safe and effective sedative. This recent addition in anesthesia armamentarium has a great role in procedural sedation and general anesthesia which is well-approved. The main beauty of this drug is, if needed its effects can be reversed by flumazenil which allows prompt termination of sedation. Remimizolam has fast predictive effect and recovery time, high procedural success rate, and minor respiratory and hemodynamic fluctuation when used for procedural sedation and general anesthesia. Although has a great potential for sedation in patients admitted to intensive care unit (ICU), some randomized trials are necessary to prove its long-term efficacy and safety in patients admitted to ICU.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
